VTGN - VistaGen Therapeutics Inc Stock Price, Fair Value and News

$3.73+0.13 (+3.61%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

VTGN Price Action

Last 7 days

-17.8%

Last 30 days

-12.0%

Last 90 days

3.0%

Trailing 12 Months

38.2%

VTGN RSI Chart

VTGN Valuation

Market Cap

147.3M

Price/Earnings (Trailing)

-2.37

Price/Sales (Trailing)

309.62

EV/EBITDA

-1.36

Price/Free Cashflow

-2.78

VTGN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

VTGN Fundamentals

VTGN Revenue

Revenue (TTM)

486.0K

Rev. Growth (Yr)

40.98%

Rev. Growth (Qtr)

5.74%

VTGN Earnings

Earnings (TTM)

-62.2M

Earnings Growth (Yr)

-49.81%

Earnings Growth (Qtr)

-28.63%

VTGN Profitability

EBT Margin

-12805.76%

Return on Equity

-93.82%

Return on Assets

-76.9%

Free Cashflow Yield

-35.94%

VTGN Investor Care

Shares Dilution (1Y)

41.85%

Diluted EPS (TTM)

-1.91

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	486.0K	0	0	0
2024	1.1M	970.5K	875.5K	698.5K
2023	0	1.4M	1.7M	1.8M
2022	1.1M	1.1M	1.6M	0
2021	1.1M	1.4M	1.5M	1.5M
2020	0	0	1.6M	1.9M
2017	1.3M	0	0	0
2016	0	0	0	0
2015	2.7M	0	0	0
2014	709.7K	1.2M	1.7M	2.2M
2013	200.4K	0	0	0
2012	1.3M	987.7K	671.7K	669.4K
2011	0	0	1.9M	1.5M
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About VistaGen Therapeutics Inc

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.

CEO	Mr. Shawn K. Singh J.D.
WEBSITE	vistagen.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	32

VistaGen Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for VistaGen Therapeutics Inc? What does VTGN stand for in stocks?

VTGN is the stock ticker symbol of VistaGen Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of VistaGen Therapeutics Inc (VTGN)?

As of Wed Dec 03 2025, market cap of VistaGen Therapeutics Inc is 147.32 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VTGN stock?

You can check VTGN's fair value in chart for subscribers.

Is VistaGen Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether VTGN is over valued or under valued. Whether VistaGen Therapeutics Inc is cheap or expensive depends on the assumptions which impact VistaGen Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VTGN.

What is VistaGen Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, VTGN's PE ratio (Price to Earnings) is -2.37 and Price to Sales (PS) ratio is 309.62. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VTGN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on VistaGen Therapeutics Inc's stock?

In the past 10 years, VistaGen Therapeutics Inc has provided -0.318 (multiply by 100 for percentage) rate of return.